Key Takeaways
- Guidance exceeded, margin rebounded: FY23 revenue of INR1,852 crores beat the INR1,800 crore target, while Q4 EBITDA margin jumped 730 bps YoY to 22.5% as freight and raw material costs normalized.
- Teva plant is the central bet: The acquired facility is expected to contribute meaningful revenue from Q3 FY24 and eventually match or exceed the Goa plant, but management warns of short-term margin pain in the first three to six months.
- Pricing stability is emerging: US prescription price erosion has slowed to low single digits in Q1 FY24, and management believes raw material pricing is approaching a "rock bottom."
- Capital return policy is now codified: One-third of free cash flow will be deployed annually into dividends and/or buybacks, a defined process that started this year.
- What to watch next quarter: Whether the Teva plant commercializes on schedule in Q3, the pace of new high-margin OTC approvals, and if the 18% EBITDA margin floor holds as employee costs normalize upward in Q1 and Q2.
Teva Facility Integration
- Scale ambition: Management targets 500 crore-plus tablets from the Teva plant in FY25, stepping up to 800 crore, making it equivalent to or larger than the current Goa facility.
- Revenue timeline: Sales revenue generation is expected to start in Q3 FY24, with full optimization visible only in Q1 FY25. New product filings from the plant will not see light until mid-FY25.
- Short-term margin drag: The first three to six months will carry investment-related pain before "tremendous gains" materialize; annual opex at 500 crore capacity is estimated at INR50-60 crores.
- Capex commitment: A substantial part of the INR143 crore balance will be spent in FY24, with roughly INR150-200 crores each year for the next two years.
- Product and geography mix: The initial product basket is small and similar to the current mix; revenue will be more European-driven at first, eventually balancing US and Europe. No product licenses were inherited from Teva, so site variations and regulatory approvals are required.
- Breakeven target: Management expects net profit breakeven by Q3 FY24.
Mark Saldanha: "I wish it was like a Ferrari where you start from a zero to 100 in 4 seconds, but it does not happen that way."
Margin Recovery & Cost Normalization
- Freight cost normalization: Freight expenses, which had peaked at 15% of revenue, have returned to pre-COVID levels, driving other expenses down from INR101 crores in Q3 to INR72 crores in Q4. Current freight levels are expected to be sustainable.
- Raw material tailwind: High-cost inventory is "almost over"; some locations have already started receiving new, lower-cost material. Q4 and Q1 FY24 material costs have further improved, and management believes pricing is approaching a rock bottom.
- Gross margin improvement: Gross margin increased 40 bps to 49.8% in Q4, though the company has not yet realized the full benefit of lower raw material prices.
- Margin floor and ambition: Q4's 18% EBITDA margin is expected to be maintained at least at that level, with management aiming to touch 20%. The Q3-to-Q4 expansion was substantially driven by raw material and freight savings.
- Employee cost normalization ahead: The Q4 decline in employee costs was seasonal, driven by bonus and incentive timing; costs will normalize upward in Q1 and Q2 of FY24.
- OTC mix benefit: The OTC proportion rose from ~55% to ~74-75%, which management expects to bring operational leverage, distribution economies, and freight cost optimization.
Pricing & Market Environment
- US pricing stabilizing: Q1 FY24 shows pricing stability with price erosion in low single digits, an improvement from Q4. Prescription products that were highly volatile have stabilized.
- Raw material price pass-through risk: Management flagged that when raw material prices decline, front-end pricing erodes quickly, creating panic and pressure even as input costs fall.
- Europe competitive environment: No visible fundamental improvement from competitor exits or better pricing trends; management described the environment as unchanged for the last 10 years.
- UK growth outperformance: The UK grew 33% YoY, driven by aggressive new product launches and market share gains; as the product basket matures, better market share, positioning, and profitability are expected to follow.
Mark Saldanha: "Whenever raw materials change, pricing erodes so fast it's never encouraging because it creates panic and even the front-end witnesses that price erosion to some extent."
Product Pipeline & R&D Strategy Shift
- Pipeline breadth: 92 products are in the pipeline across markets, with the company being selective based on its strengths. Certain molecules in the basket are niche with more restricted competition; none are first-to-file.
- R&D ambition increasing: Management is now targeting complex molecules, clinical molecules, and molecules requiring clinical studies, a departure from its historically conservative approach driven by cash flow preservation. R&D spend will increase significantly over the next two to three years.
- New OTC launches targeted: Approvals are expected in the digestive range, pain segment, cough and cold, and from the UK plant in antidepressants and cardiovascular. These are expected to carry higher margins.
- API backward integration: DMF filings for five molecules are expected around September 2023, with own-license incorporation three to four months after filing.
Mark Saldanha: "Historically, we avoided or we basically restrained from going into such complexities because it's high-risk, high-gain strategy, but we were very conservative with our outlook and our cash flow."
Capital Allocation & Inorganic Strategy
- Codified capital return: One-third of free cash flow will be deployed annually into dividends and/or buybacks. A dividend of INR0.5 per share was announced for FY23, and the share buyback was completed.
- OrbiMed's active role: OrbiMed has converted warrants and is involved on the board, helping identify M&A targets, providing market intelligence, and facilitating approaches to potential acquisition targets. Management emphasized that OrbiMed is not running the company.
- Inorganic exploration underway: Management has conducted due diligence on over two companies in the last eight months, exploring Europe and India geographies. No fixed ticket size is defined; qualitative synergy and value addition are the key criteria.
- Indore land deprioritized: The Indore land award has been deprioritized; focus is entirely on the Teva plant acquisition and integration.
Mark Saldanha: "If history has to say something about us, we are very choosy in how we go about doing our inorganic strategies and how we acquire companies."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Teva plant revenue start | Meaningful revenue contribution to begin | Q3 FY24 |
| Teva plant net profit breakeven | Breakeven expected | Q3 FY24 |
| Teva plant full optimization | Full-fledged revenue generation | Q1 FY25 |
| Teva plant volume target | 500 crore-plus tablets | FY25 |
| Teva plant capex | INR150-200 crores per year | FY24 and FY25 |
| Revenue milestone | Cross INR2,000 crores, then a new undisclosed benchmark beyond | Coming years |
| EBITDA margin floor | Maintain at least 18% | FY24 |
| EBITDA margin ambition | Aim to touch 20% | FY24 |
| Capital return policy | One-third of free cash flow to dividends and/or buyback | Annual process |
| DMF filings | Five molecules to be filed | Around September 2023 |
| API backward integration | Own license incorporation after DMF filing | Three to four months post-filing (H2 FY24) |
| New product filings from Teva plant | First filings to see light | Mid-FY25 |
| Tax rate | Effective tax rate ~23% | FY24 onward |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Operating revenue | ₹486 cr, +16.3% YoY |
| US and North America revenue | ₹193.5 cr, +12.8% YoY |
| UK and EU Formulation revenue | ₹206.3 cr, +33.1% YoY |
| Gross profit | ₹242.1 cr, +17.3% YoY |
| Gross margin | 49.8%, +40 bps YoY from 49.4% |
| EBITDA | ₹109.5 cr, +72.1% YoY |
| EBITDA margin | 22.5%, +730 bps YoY from 15.2% |
| Profit after tax | ₹82.7 cr, +178.9% YoY |
| Full-year FY23 operating revenue | ₹1,852 cr, +24.2% YoY |
| Full-year FY23 EBITDA margin | 18.3%, +100 bps YoY from 17.4% |
| Full-year FY23 PAT | ₹265 cr, +42% YoY |
| Full-year FY23 EPS | ₹6.4 per share, +42% YoY |
| Full-year FY23 free cash flow | ₹183.8 cr |
| Cash and equivalents | ~₹715 cr |
| US OTC proportion of US business | ~74–75%, up from ~55% |
| Existing capacity utilization (excl. Teva) | 70% |
| Teva facility target volume (FY25) | 500 crore-plus tablets or pills |
| Teva facility total investment (incl. acquisition) | ₹200 cr; acquisition cost ₹56 cr, balance ₹144 cr for capacity expansion |
| Freight cost, US containers | ~$3,000 per container, down from peak of $12,500 |
| Freight cost, UK containers | ~$2,000 per container, down from peak of $9,000 |
| Effective tax rate guidance (FY24) | ~23%, up from 21% in FY23 due to UK corporate tax rate increase from 20% to 25% |
| Dividend announced (FY23) | ₹0.5 per share, 50% of face value of ₹1 each |